AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a KOL webinar on amyloid plaque PET imaging in Alzheimer’s Disease as a surrogate of clinical efficacy on Thursday, November 9, 2023 at 10:00am ET / 4:00pm CET. To register, click here.
The event will feature Prof. Victor Villemagne, MD (University of Pittsburgh), who will discuss the heightened interest in amyloid plaque PET imaging and the methodology, mechanisms, and clinical implications of plaque lowering in light of recent successful trials.
The AC Immune team will also highlight its anti-Abeta active immunotherapy candidate, ACI-24.060, currently being evaluated in the ongoing Phase 1b/2 ABATE study for the treatment of Alzheimer’s disease. Initial amyloid-PET imaging analyses in Alzheimer’s patients to assess amyloid plaque reduction after 6 months of treatment with ACI-24.060 in the ABATE trial are anticipated in the first half of 2024.
A live question and answer session will follow the presentations.
About Prof. Victor Villemagne, MD
Prof. Victor Villemagne, MD graduated Cum Laude in 1983 from the Universidad Nacional de Buenos Aires, Argentina. He was awarded a Post-Doctoral Fellowship in Nuclear Medicine in 1984 and continued his post-graduate studies at the Division of Nuclear Medicine at The Johns Hopkins Medical Institutions. He subsequently furthered his molecular neuroimaging training at NIDA (NIH), and at the University of Pittsburgh.
In 2003 he joined the Neurodegeneration group at the University of Melbourne, where he performed several preclinical and clinical studies of new tracers for amyloid and tau imaging, and in 2020, he joined the Dept. of Psychiatry at the University of Pittsburgh. His research involves national and international collaborations with neuroscientists, chemists, molecular biologists, clinical neurologists, molecular imaging experts, and is regularly invited to present his research at international meetings. With an h-index of 83, he has authored or co-authored several book chapters and requested reviews on molecular imaging, and more than 440 original research publications. Among other honors, he has received the de Leon Prize in Neuroimaging (Boston, USA, 2013), the Christopher Clark Award for the Continuing Advancement in the Field of Human Amyloid Imaging, (Miami, USA, 2014), and the Kuhl-Lassen award by the Society of Nuclear Medicine and Molecular Imaging (Philadelphia, USA, 2018). Since 2016 he has been recognized as one of The World's Most Influential Scientific Minds based on his citations being in the top 1% in the world in the field of Neuroscience.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| Head of Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | U.S. Investors Corey Davis, Ph.D. LifeSci Advisors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward- looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
